Clinical trial · Observational
Circular RNA and Chemerin in Breast Cancer Patient
Circular RNA and Chemerin in Blood of Breast Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aimed to evaluate the role of serum chemerin as a biomarker of breast cancer. and To investigate the diagnostic value of hsa\_circ\_0001785 (Circ-ELP3) and hsa\_circ\_100219 (Circ-FAF1) in serum samples of breast cancer patients to find out whether these circRNAs can utilize as a diagnostic and prognostic biomarker for human breast cancer assessment and make Correlation between serum chemerin levels , serum Circ-FAF1 , serum CircELP3 and classical tumor markers (CEA + CA15-3). andTo elucidate if there is a difference between metastatic and non-metastatic cases as regard serum chemerin levels, serum Circ-FAF1 or Circ-ELP3.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood sample | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- breast cancer leasion
- interventionNames
- Diagnostic Test: blood sample
- label
- benign breast lesion
- interventionNames
- Diagnostic Test: blood sample
Primary outcomes (1)
- measure
- measure chemerin and Circular RNA in breast cancer patients
- timeFrame
- 2 years
- description
- To elucidate if there is a difference between metastatic and non-metastatic cases as regard serum chemerin levels, serum Circ-FAF1 or Circ-ELP3.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * histopathological diagnosis of breast cancer Exclusion Criteria: * history of other types of cancers * history of HIV * history of any therapeutic interventions in form of chemo or hormonal therapy before specimen collection
References
Publications (2)
- BACKGROUNDSong Y, Zhu X, Lin Z, Luo L, Wen D. The potential value of serum chemerin in patients with breast cancer. Sci Rep. 2021 Mar 22;11(1):6564. doi: 10.1038/s41598-021-85986-w. PMID 33753802
- BACKGROUNDOmid-Shafaat R, Moayeri H, Rahimi K, Menbari MN, Vahabzadeh Z, Hakhamaneshi MS, Nouri B, Ghaderi B, Abdi M. Serum Circ-FAF1/Circ-ELP3: A novel potential biomarker for breast cancer diagnosis. J Clin Lab Anal. 2021 Nov;35(11):e24008. doi: 10.1002/jcla.24008. Epub 2021 Sep 21. PMID 34545638